GENENTECH, INC for GENENTECH INC
What was lobbied
6 issue areas, each in the filer's own words, with who lobbied on it and where.
Pharmacy PHA
Monitor Drug Safety and legislation; Advocacy related to ensuring access to necessary medicines
| Lobbyist | Covered position, as disclosed |
|---|---|
| DARIN GARDNER | director |
| EVAN MORRIS | Vice President of Government Affairs |
Copyright/Patent/Trademark CPT
General Patent reform issues S. 23: America Invents Act H.R. 1249 Leahy-Smith America Invents Act; Patent Reform Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| KATHERINE RAAB | Director |
Taxation/Internal Revenue Code TAX
General Tax issues and tax extenders
| Lobbyist | Covered position, as disclosed |
|---|---|
| ELI KOGAN | Asst. Director |
Health Issues HCR
Implementation of H.R. 1: Medicare Prescription Drug and Modernization Act of 2003; Issues relating to PDUFA stimulus. Issues relating to comparative effectiveness and CMS coverage of FDA approved therapies. Issues related to PPS rule involving stroke guidelines. Implementation of the follow on biologic provision in P.L. 111-148 Patient Protection and Affordable Care Act. Legislation on public health preparedness and response related to pandemic influenza. Influenza Pandemic preparedness federal, state and local levels. Legislation on screening, care and treatment for hepatitis.; Prescription Drug User Free Act; Avastin - Use in breast cancer treatment; general patent reform issues; ASP +6 Melanoma research Foundation; Implementation of the Affordable Care of Act of 2010
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | Director |
| DARIN GARDNER | Director |
| KATHERINE RAAB | Director |
Medicare/Medicaid MMM
Medicare Prescription Drug and Modernization Act of 2003; Issues relating comparative effectiveness and CMS coverage of FDA approved therapies. Issues related to the PPS rule involving stroke guidelines. Proposals to reduce Medicare payment for Part B biologics; payment policies for prescription drugs
| Lobbyist | Covered position, as disclosed |
|---|---|
| DARIN GARDNER | Director |
| ELI KOGAN | Assistant Director |
| EVAN MORRIS | Vice President of Government Affairs |
Budget/Appropriations BUD
Budget/Appropriations: FY13 appropriations for FDA as well as the potential outcomes for negotiations on altering sequestration targets via legislation. We also monitored both Chambers of Congress on issues related to comprehensive tax reform, tax treatment of foreign-owned U.S. corporations, and tax extenders (R&D tax credit); various issues related to the budget and appropriations process
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | Director |
| DARIN GARDNER | Director |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.